Market revenue in 2023 | USD 200.7 million |
Market revenue in 2030 | USD 293.7 million |
Growth rate | 5.6% (CAGR from 2023 to 2030) |
Largest segment | Biologics |
Fastest growing segment | Therapy Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Wound Care Dressings, Biologics, Therapy Devices, Antibiotic Medications |
Key market players worldwide | ConvaTec Group PLC, 3M Co, Coloplast A/S ADR, Smith & Nephew PLC, Medtronic PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetic foot ulcer treatment market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 36.47% in 2023. Horizon Databook has segmented the France diabetic foot ulcer treatment market based on wound care dressings, biologics, therapy devices, antibiotic medications covering the revenue growth of each sub-segment from 2018 to 2030.
The French government is undertaking initiatives to improve the healthcare structure in France. Hence, the major international players are collaborating with local players to launch, market, and distribute their products. Therefore, the local players are gaining significant market shares in the region owing to these collaborations.
The France diabetic foot ulcer treatment market is anticipated to witness significant growth over the forecast period owing to increase in prevalence of diabetes and local presence of several key players. For instance, according to ResearchGate, the prevalence of diabetes in France is estimated to be 6%.
Furthermore, the number of diabetic patients in France has doubled over the past decade. It has the highest prevalence among all other chronic covered by the French government. As per European Commission in 2017, the mortality in France due to diabetes is around 8.0% per year.
Horizon Databook provides a detailed overview of country-level data and insights on the France diabetic foot ulcer treatment market , including forecasts for subscribers. This country databook contains high-level insights into France diabetic foot ulcer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account